Floatz Rating
CCC49/100
Confidence
Indicative
Sponsor
Yonsei University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
34Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05436990CT.gov Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acral Lentiginous Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vactosertib (this asset) | Yonsei University | P2 | CCC · 49 |
| Pembrolizumab | Yonsei University | P2 | BB |
| Nilotinib | Institute of Cancer Research, United Kingdom | P2 | B |
| Nivolumab | Fred Hutchinson Cancer Center | P2 | B |
| Rivoceranib | Peking University Cancer Hospital & Institute | P3 | B |
| Imatinib | National Cancer Institute (NCI) | P2 | B |
| ibi310 | Innovent Biologics (Suzhou) Co. Ltd. | P3 | B |
| Catequentinib | Qilu Hospital of Shandong University | P2 | B |
| Interferon Alfa-2B | Innovent Biologics (Suzhou) Co. Ltd. | P3 | B |
+20 more in the Acral Lentiginous Melanoma cohort
Other indications for Vactosertib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P2 | CCC · 50 |
| Mucosal Melanoma | — | P2 | CCC · 49 |
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 49 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vactosertib in Acral Lentiginous Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vactosertib-acral-lentiginous-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →